Table 6 Co-medications dispensed to triptan non-users and to users without and with overuse
From: Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data
Triptan non-users n = 5,885,425 | Triptan users without overuse n = 31,092 | Triptan users with overuse n = 1970 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | OR# | 95% CI | n | % | OR# | 95% CI | |
Betablockers | 493,457 | 8.4 | 3455 | 11.1 | 1.4 | 1.3–1.4 | 376 | 19.1 | 1.9 | 1.7–2.1 |
Flunarizine | 10,617 | 0.2 | 1425 | 4.6 | 26.6 | 25.1–28.6 | 162 | 8.2 | 1.9 | 1.6–2.2 |
Topiramate or valproate | 26,605 | 0.4 | 1381 | 4.4 | 10.2 | 9.7–10.8 | 240 | 12.2 | 3.0 | 2.6–3.5 |
Tricyclic antidepressants | 49,935 | 0.9 | 1319 | 4.2 | 5.2 | 4.9–5.5 | 166 | 8.4 | 2.1 | 1.8–2.5 |
SSRI | 459,917 | 7.8 | 5596 | 18.0 | 2.6 | 2.5–2.7 | 444 | 22.5 | 1.3 | 1.2–1.5 |
SNRI | 63,009 | 1.1 | 1412 | 4.5 | 4.4 | 4.2–4.6 | 116 | 5.9 | 1.3 | 1.1–1.6 |
NaSSA | 85,402 | 1.5 | 1019 | 3.3 | 2.3 | 2.2–2.5 | 84 | 4.3 | 1.3 | 1.0–1.6 |
Other antidepressants or serotonergic drugs | 168,020 | 2.9 | 2360 | 7.6 | 2.8 | 2.7–2.9 | 189 | 9.6 | 1.3 | 1.1–1.5 |